Transcatheter Mitral & Tricuspid Patents: Leaders & Filing Trends 2026
- 38.5% concentration. The five leading assignees hold 482 of the 1,251 records in scope, so freedom-to-operate work should start with their claim sets, not a broad landscape scan.
- Filing has cooled from its 2019 peak. Annual filings ran 162 in 2019 and fell from 131 in 2021 to 53 in 2024, a 60% drop across that span — a signal to watch, not to over-read given publication lag.
- A61F implant claims dominate. 76.3% of the 1,251 records carry an A61F implant/prosthesis class, while imaging and informatics classes (G06T, G16H) sit under 5% each — a gap worth checking before filing there.
Filing growth compares 2021 (131 records) with 2024 (53) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,251 records in scope (CR5), not by the ranked leaders only.
What the transcatheter mitral and tricuspid device patent record shows
Transcatheter mitral and tricuspid device patenting covers the mechanical and delivery problems that separate a bench-tested valve from an implantable one: annular anchoring, device migration control, delivery route selection, and accommodating anatomical variability across patients whose native valve geometry does not match a single stent frame. The 1,251 records in scope span 2015 through the current data cut-off, with the most recent year necessarily undercounted because publication trails filing by roughly 18 months.
The claim language clusters around edge-to-edge repair mechanisms and anchoring geometries first, with left ventricular outflow tract obstruction and imaging-guided placement appearing as secondary but recurring themes across the corpus.
Filing trend and technology composition
Two views of the same 1,251-record corpus: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.
Filing trend, 2017–2026
Annual filings ran 71 in 2017, climbed to a peak of 162 in 2019, and by the last complete year had fallen to 53 in 2024 from 131 in 2021 — a 60% decline across that three-year span. Treat 2025 and 2026 figures as still filling in rather than as evidence of a further drop.
Technology composition by IPC subclass
A61F implants and prostheses appear on 76.3% of the 1,251 records, far ahead of A61B diagnosis and surgery methods at 34.8% and A61M body-fluid devices at 16.8%. Because a single record can carry several IPC codes, these shares add up to more than 100% and should not be read as a partition of the field.
Shares are the percentage of the 1,251 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Transcatheter Mitral and Tricuspid Devices with Eureka
This page is one run against one query. Ask Eureka your own question about transcatheter mitral and tricuspid devices and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative recent filing
Split type precisely-anchorable transcatheter mitral valve system (CA3238537A1)
A split-frame transcatheter mitral valve system pairs an anchoring stent shaped to a patient's own reconstructed anatomy with a separately delivered biological valve component, so the anchor is seated and deployed first and the valve is then aligned and seated into it for a patient-specific fit.Filed by Beijing Balance Medical Technology Co., Ltd., dated 2023-05-25 — illustrates the shift toward two-piece, image-matched anchor-and-valve architectures rather than single-frame delivery.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20110319989A1 | Transcatheter mitral valve prosthesis | 782 |
| 2 | US20130331929A1 | Means for Controlled Sealing of Endovascular Devices | 607 |
| 3 | US20140214159A1 | Prosthetic valves and related inventions | 569 |
| 4 | US8579964B2 | Transcatheter mitral valve prosthesis | 569 |
| 5 | US20140052237A1 | Methods and apparatus for engaging a valve prosthesis with tissue | 559 |
| 6 | US20140257467A1 | Prosthetic valve with Anti-pivoting mechanism | 503 |
| 7 | US8728155B2 | Disk-based valve apparatus and method for the treatment of valve dysfunction | 494 |
| 8 | WO2011137531A1 | Transcatheter mitral valve prosthesis | 471 |
| 9 | WO2013028387A2 | Improvements for prosthetic valves and related inventions | 456 |
| 10 | US20160113766A1 | Systems and methods for heart valve therapy | 442 |
Citation counts favour older records simply because they have had longer to accumulate citations inside this searched corpus — read them as a signal of influence on the field's early architecture, not a ranking of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-outs from the corpus that matter more than the raw counts on their own.
The field is concentrated but not closed
482 of the 1,251 records in scope sit with five assignees, and the top 10 combined hold 55.2% (690 records). That leaves close to half the corpus spread across a long tail of single- and few-filing entrants, which is where a narrowly drafted claim still has room.
Filing has pulled back from its 2019 peak
Annual filings peaked at 162 in 2019 and have declined through the last complete reporting year. That is a real pullback in new filing activity, not a sign the underlying technology is settled — mechanical anchoring and delivery problems in this space remain open.
Implant and prosthesis claims dominate the record
A61F implant/prosthesis claims outnumber every other class by a wide margin, while imaging (G06T, 3.0%) and informatics (G16H, 4.1%) classes remain thin. That gap is either unclaimed opportunity or a sign the imaging-integration angle has not yet been worked hard in claim language.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to transcatheter mitral and tricuspid devices, with the prior art for and against each one.
Who is filing, and where the pack thins out
The ranked leaders account for a majority of the corpus, but momentum data suggests the leaders themselves are filing less than they were a few years ago.
One assignee sits well clear of the field
The leading assignee holds 194 records against a fifth-place figure of 57 and a tenth-place figure of 38 — a steep drop-off that marks this as a leader-plus-pack structure rather than an even spread.
Even active filers are pulling back
Several named assignees show flat or negative year-on-year momentum in the latest tracked year, including one leading filer down 75% and another down to zero from a prior filing. That pattern fits the broader 2021-to-2024 pullback rather than a single company's retreat.
Co-filing is rare and mostly internal
Only 10 co-assignee pairings appear across the corpus, and the strongest is a name variant pairing rather than a cross-company collaboration. Genuine inter-company co-filing, such as a government research partner alongside a device maker, is the exception rather than the norm here.
| Assignee | Recent year | YoY |
|---|---|---|
| Neovasc Tiara Inc. | 1 | -50% |
| Caisson Interventional LLC | 1 | 0% |
| Transmural Systems LLC | 1 | 0% |
| Medtronic Inc. | 1 | -75% |
| Evalve, Inc. | 1 | 0% |
| Tendyne Holdings Inc. | 0 | -100% |
| Opus Medical Therapies LLC | 0 | — |
| Edwards Lifesciences Corp | 0 | -100% |
Where to take this next
The landscape numbers point to specific next steps depending on whether you are clearing freedom-to-operate or scouting where to file.
Run a freedom-to-operate check on the leading assignees
With 38.5% of the corpus held by five assignees, a targeted claim-by-claim review of their anchoring and edge-to-edge repair patents will surface more risk than a broad keyword scan.
Search assignee portfolios in EurekaTest claim language against the under-claimed branches
Imaging-guided placement and informatics-linked fit sit under 5% of records each despite the field's reliance on patient-specific anatomy — a narrow, well-drafted claim there faces less prior art.
Explore white space with EurekaWatch the 2025–2026 filings as they publish
The apparent pullback from 2021 to 2024 is real but the most recent two years are still filling in under normal publication lag, so re-check momentum in a future pull before treating the field as settled.
Track filing trends in EurekaQuestions practitioners ask about this field
One assignee leads the corpus with 194 of the 1,251 records in scope, well ahead of the fifth-ranked filer at 57 and the tenth-ranked filer at 38. The top five assignees combined hold 482 records, or 38.5% of the total, and the top ten hold 690 records, or 55.2%. That leaves a substantial long tail of single- and few-filing entrants across the remaining ranked companies, so the field is concentrated at the top without being closed off to new filers.
Filing peaked at 162 records in 2019 and has declined since, falling from 131 in 2021 to 53 in 2024, a 60% drop over that three-year span. That is the most recent period that can be treated as reasonably complete. Figures for 2025 and 2026 are still understated because publication typically lags the actual filing date by around 18 months, so the true current-year picture will only become clear over the next reporting cycles.
Implant and prosthesis claims under IPC class A61F appear on 76.3% of the 1,251 records, making anchoring geometry and valve-frame design the dominant claim territory. Diagnosis and surgical method claims (A61B) appear on 34.8% of records, and body-fluid device claims (A61M) on 16.8%. Imaging (G06T) and healthcare informatics (G16H) classes are comparatively thin, each under 5%, suggesting that image-guided placement and data-driven fit have not yet been claimed as heavily as the mechanical hardware itself.
The thinnest IPC classes relative to the corpus size are informatics (G16H, 4.1%), imaging processing (G06T, 3.0%), polymer compositions (C08L, 1.9%) and electrotherapy (A61N, 1.7%), all sitting well below the dominant A61F implant class. That gap likely reflects under-exploited claim territory around imaging-guided anchor placement, delivery route selection logic, and leaflet material composition rather than a lack of underlying engineering activity. A narrowly drafted claim in one of these branches faces less direct prior art than a general anchoring or edge-to-edge repair claim.
The most-cited records in the corpus, including early transcatheter mitral valve prosthesis filings, carry citation counts in the 500-to-780 range, reflecting their role as foundational architecture rather than current state of the art. High citation counts inside a searched corpus tend to favour older documents simply because they have had more time to accumulate citations. A new filer should treat these as the baseline prior art to design around, not as a signal that the underlying claim space is still open.
Research Transcatheter Mitral and Tricuspid Devices in depth with Eureka
Go past this page: query the whole transcatheter mitral and tricuspid devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.